The role of the pharmacist in the prevention of medication-related osteonecrosis of the jaw

Andrew Sturrock

Research output: Contribution to journalArticlepeer-review

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a rare adverse effect of several anti-resorptive and anti-angiogenic drugs that typically presents following a dental extraction. MRONJ is difficult to treat and can have a significant negative effect on quality of life; therefore, the implementation of preventative measures is recommended.
The multidisciplinary healthcare team should work collectively to educate patients on the need for good oral hygiene and ensure that patients undergo remedial dental work prior to the initiation of implicated medicines. As medicine experts, a major aspect of the pharmacist’s role is to educate both patients and other healthcare professionals on the safe and effective use of medicines. Consequently, there is an opportunity for pharmacists working in all settings to contribute to the prevention of MRONJ.
This article provides a summary of the most important background information in relation to the prevention of MRONJ, and outlines the potential opportunities for pharmacists working in community pharmacy, secondary care and general practice.
Original languageEnglish
JournalThe Pharmaceutical Journal
DOIs
Publication statusPublished - 2019
Externally publishedYes

Keywords

  • Community pharmacy
  • interprofessional working
  • medication-related osteonecrosis of the jaw
  • medicine safety
  • MRONJ
  • prevention
  • primary care
  • oral health
  • secondary care

Fingerprint

Dive into the research topics of 'The role of the pharmacist in the prevention of medication-related osteonecrosis of the jaw'. Together they form a unique fingerprint.

Cite this